Revolution Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revolution Medicines, Inc. (RVMD) CEO to speak at healthcare conferences. Mark A. Goldsmith, M.D., Ph.D., will be featured at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum. Webcasts available on the company's website.

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23^rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.

Details of the company’s participation are as follows:

• 23^rd Annual Needham Healthcare Conference
  Conference Dates: April 8-11, 2024
  Fireside Chat Time/Date: 1:30 – 2:10 p.m. ET on Thursday, April 11, 2024
  Location: Virtual; webcast available

• Stifel Targeted Oncology Forum
  Conference Dates: April 16-17, 2024
  Fireside Chat Time/Date: 3:30 – 3:55 p.m. ET on Tuesday, April 16, 2024
  Location: Virtual; webcast available

To access the live webcasts of the Needham and Stifel fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

When is Mark A. Goldsmith scheduled to speak at the 23rd Annual Needham Healthcare Conference?

Mark A. Goldsmith is scheduled to speak at the 23rd Annual Needham Healthcare Conference on Thursday, April 11, 2024, from 1:30 – 2:10 p.m. ET.

Where can investors access the live webcasts of the Needham and Stifel fireside chats?

Investors can access the live webcasts of the Needham and Stifel fireside chats on the 'Events & Presentations' page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations.

How long will the replay of each webcast be available on the Revolution Medicines website?

The replay of each webcast will be available on the Revolution Medicines website for at least 14 days following the conference.